Nasus Pharma Ltd. (NYSE MKT:NSRX) — Stock Price
Nasus Pharma Ltd. (NYSE MKT:NSRX) is currently trading at $2.90 USD, up 1.05% today. Over the past 52 weeks, shares have ranged between $2.01 and $9.15. This page tracks Nasus Pharma Ltd.'s live share price on the NYSE MKT exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market value of Nasus Pharma Ltd..
Nasus Pharma Ltd. (NSRX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Nasus Pharma Ltd.'s daily closing share price and trading volume on the NYSE MKT exchange over the past year, giving a clear view of recent price momentum and liquidity.
Nasus Pharma Ltd. Income Statement — Revenue, Profit & Earnings by Year
Nasus Pharma Ltd.'s annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Research & Development | $2.24 Million | $335.00K | $567.00K | $1.12 Million |
| SG&A | $2.67 Million | $743.00K | $580.00K | $926.00K |
| Total Operating Expenses | $4.90 Million | $1.08 Million | $1.15 Million | $2.04 Million |
| Operating Income | $-4.90 Million | $-1.08 Million | $-1.15 Million | $-2.04 Million |
| EBITDA | — | $-1.52 Million | $-956.00K | $-2.13 Million |
| EBIT | — | — | — | — |
| Interest Expense | — | $29.00K | $49.00K | $18.00K |
| Income Before Tax | $-5.80 Million | $-1.55 Million | $-1.00 Million | $-2.15 Million |
| Income Tax Expense | — | — | — | — |
| Net Income | $-5.86 Million | $-1.53 Million | $-1.05 Million | $-1.71 Million |
Nasus Pharma Ltd. Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Nasus Pharma Ltd.'s financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Assets | $5.00 Million | $717.00K | $444.00K | $417.00K |
| Total Current Assets | $4.86 Million | $457.00K | $444.00K | $417.00K |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | $3.05 Million | $0.00 | — | — |
| Net Receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | — | — | — | — |
| Total Liabilities | $2.24 Million | $3.93 Million | $4.24 Million | $3.20 Million |
| Total Current Liabilities | $2.16 Million | $3.93 Million | $4.24 Million | $3.20 Million |
| Long-term Debt | — | — | — | — |
| Net Debt | — | $1.52 Million | $2.26 Million | $1.42 Million |
| Total Stockholder Equity | $2.77 Million | $-3.21 Million | $-3.80 Million | $-2.79 Million |
| Retained Earnings | $-18.52 Million | $-12.66 Million | $-11.13 Million | $-10.08 Million |
Nasus Pharma Ltd. Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Nasus Pharma Ltd. generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Cash Flow | $-4.92 Million | $-665.00K | $-1.03 Million | $-1.21 Million |
| Capital Expenditures | $14.00K | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | $-4.93 Million | $-665.00K | $-1.03 Million | $-1.21 Million |
| Investing Cash Flow | — | — | — | — |
| Financing Cash Flow | $8.92 Million | $770.00K | $1.05 Million | $1.47 Million |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | $447.00K | $10.00K | $39.00K | $23.00K |
| Depreciation | — | — | — | — |
| Change in Cash | $980.00K | $101.00K | $39.00K | $-143.00K |
Nasus Pharma Ltd. Earnings History — EPS Actual vs. Analyst Estimates
Track Nasus Pharma Ltd.'s quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Feb 25, 2026 | 0.00 | -0.53 | +100.00% |
| Dec 03, 2025 | -0.14 | -0.14 | +0.00% |
| Sep 03, 2025 | -0.09 | 0.00 | — |
| Mar 21, 2025 | -0.09 | 0.00 | — |